Table 4. . Analysis of additional characteristics associated with PFS and OS in the univariate analysis.
| Characteristic | N | PFS (m) | HR (95% CI) | p-value | OS (m) | HR (95% CI) | p-value |
|---|---|---|---|---|---|---|---|
| Histology Transitional Other/rare |
60 12 |
4.4 2.6 |
1.65 (0.82–3.32) |
0.2 |
14.3 4.7 |
1.92 (0.9–4.06) |
0.10 |
| Surgery on T No Yes |
20 52 |
2.8 5.1 |
0.37 (0.21–0.66) |
<0.01 |
7.1 17.3 |
0.39 (0.19–0.77) |
<0.01 |
| Age, years <70 >70 |
42 30 |
3.5 4.1 |
0.96 (0.55–1.66) |
0.9 |
10.5 15.3 |
1.01 (0.53–1.92) |
1 |
| First-line tx Carboplatin-based Cisplatin-based |
20 52 |
3.0 4.3 |
0.61 (0.34–1.09) |
0.10 |
11.7 14.3 |
0.64 (0.32–1.29) |
0.2 |
| Status at diagnosis M0 M1 |
49 23 |
6.2 2.8 |
3.16 (1.78–5.62) |
<0.01 |
17.3 6.3 |
2.85 (1.45–5.63) |
<0.01 |
| Visceral mets No Yes |
24 48 |
4.6 3.1 |
1.53 (0.86–2.74) |
0.3 |
17.3 11.6 |
1.61 (0.80–3.21) |
0.2 |
| Bone mets No Yes |
46 26 |
7.4 2.8 |
2.71 (1.55–4.75) |
<0.01 |
24.5 4.7 |
4.5 (2.30–8.80) |
<0.01 |
| Liver mets No Yes |
55 17 |
4.4 2.9 |
1.18 (0.63–2.21) |
0.6 |
11.7 7.1 |
1.42 (0.71–2.87) |
0.3 |
| ECOG PS 0 1–2 |
45 27 |
5.3 2.5 |
2.41 (1.39–4.16) |
<0.01 |
15.7 4.7 |
2.95 (1.55–5.63) |
<0.01 |
| Hb basal >10 <10 |
59 13 |
4.4 2.7 |
1.48 (0.74–2.95) |
0.3 |
15.3 6.3 |
1.75 (0.82–3.74) |
0.1 |
| Bellmunt 0 1 2 3 |
37 18 14 3 |
5.3 2.7 2.8 1.6 |
1.80 (0.94–3.45) 1.76 (0.86–3.6) 5.88 (1.72–20.1) |
0.01 |
15.7 5.3 6.3 2.5 |
2.52 (1.18–5.38) 2.35 (0.98–5.61) 7.41 (2.08–26.3) |
<0.01 |
Hb: Hemoglobin; m: Months; Mets: Metastasis; PS: Performance status (ECOG); T: Primary tumor; Tx: Treatment.